论文部分内容阅读
目的:建立分泌高水平白细胞介素-6(IL-6)的耐紫杉醇卵巢癌细胞株的小鼠移植瘤模型,评估抗IL-6单克隆抗体Siltuximab(CNTO328)对异种移植肿瘤生长的影响。方法:选用3～4周龄的雌性裸小鼠36只,第1天用5×106mL-1SKOV-3TR细胞和基质胶的混悬液作鼠皮下注射,2周后分成6组,分别给予腹腔注入生理盐水、非特异性抗体F105(20mg/kg)、Siltuximab(20mg/kg)、紫杉醇(20mg/kg)、紫杉醇(20mg/kg)和Siltuximab(20mg/kg)混合液、紫杉醇(20mg/kg)和非特异性抗体F105(20mg/kg)混合液。每周治疗2次,持续5周。每天检查小鼠健康状况和肿瘤生长情况。结果:各组肿瘤体积比较,差异无统计学意义(F组间=2.820,P=0.310;F时间=3.020,P=0.230;F交互=2.950,P=0.280)。结论:Siltuximab对裸鼠体内卵巢癌耐药细胞SKOV-3TR移植瘤的生长无明显影响。
OBJECTIVE: To establish a mouse xenograft model of paclitaxel-resistant ovarian cancer cell line secreting high levels of interleukin-6 (IL-6) and evaluate the effect of anti-IL-6 monoclonal antibody Siltuximab (CNTO328) on xenograft tumor growth. Methods: Thirty-six female nude mice aged 3 to 4 weeks were selected and injected with a suspension of 5 × 106 mL-1 SKOV-3 TR cells and Matrigel on the first day for subcutaneous injection. After 2 weeks, the mice were divided into 6 groups, (20 mg / kg), paclitaxel (20 mg / kg), a mixture of paclitaxel (20 mg / kg) and Siltuximab (20 mg / kg), paclitaxel (20 mg / kg) And non-specific antibody F105 (20 mg / kg). Treat twice weekly for 5 weeks. Check the health and tumor growth of mice daily. Results: There was no significant difference in tumor volume between groups (F = 2.820, P = 0.310; F time = 3.020, P = 0.230; F interaction = 2.950, P = 0.280). Conclusion: Siltuximab has no significant effect on the growth of SKOV-3TR xenografts in nude mice.